{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:31:14Z","timestamp":1786710674746,"version":"build-2736575974"},"reference-count":34,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019501","name":"Universidad Peruana Cayetano Heredia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019501","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Background: Helicobacter pylori eradication rates have declined globally due to rising antibiotic resistance, challenging the effectiveness of standard triple therapy. High-dose dual therapy has emerged as a simplified alternative supported by pharmacodynamic rationale. We aimed to compare the real-world effectiveness, adherence, and safety of high-dose dual therapy versus optimized clarithromycin-based triple therapy in routine gastroenterology practice.  Methods: We conducted a prospective, multicenter observational cohort study in adult patients with confirmed H. pylori infection treated with either high-dose dual therapy (amoxicillin 1 g three times daily plus esomeprazole 40 mg three times daily for 14 days) or optimized clarithromycin-based triple therapy (amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and esomeprazole 40 mg twice daily for 14 days) according to physician decision. Eradication was assessed by carbon-14 urea breath test \u22654 weeks after therapy. Comparative effectiveness was estimated with effect measures, 95% confidence intervals (CI), and predefined sensitivity analyses for incomplete test-of-cure follow-up.  Results: Among 218 treated patients, 104 completed post-treatment breath testing. Eradication rates were 80.4% with high-dose dual therapy and 81.3% with triple therapy (absolute difference \u22120.9%; 95%CI \u221216.3 to 14.5; P=0.91). Moderate-to-high adherence was observed in 51.5% vs 67.6%, respectively (P=0.19). Adverse events were more frequent with high-dose dual therapy (70.8% vs 58.9%), although the difference was not statistically significant. Mainly gastrointestinal intolerance and taste disturbance. Sensitivity analyses across plausible missing-outcome scenarios showed stable comparative results.  Conclusion: In prospective real-world practice, high-dose dual therapy achieved eradication effectiveness comparable to optimized triple therapy, with favorable tolerability. These findings support high-dose dual therapy as a pragmatic and clinically attractive alternative in settings with evolving resistance and adherence constraints.<\/jats:p>","DOI":"10.1590\/s0004-2803.24612026-014","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:34:42Z","timestamp":1786707282000},"source":"Crossref","is-referenced-by-count":0,"title":["REAL-WORLD EFFECTIVENESS OF HIGH-DOSE DUAL THERAPY VS OPTIMIZED CLARITHROMYCIN TRIPLE THERAPY FOR HELICOBACTER PYLORI: A PROSPECTIVE COHORT STUDY WITH TEST-OF-CURE SENSITIVITY ANALYSES"],"prefix":"10.1590","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3578-4780","authenticated-orcid":false,"given":"Alejandro","family":"UGARTE LASTRA","sequence":"first","affiliation":[{"name":"Universidad Peruana Cayetano Heredia,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2067-0805","authenticated-orcid":false,"given":"David E.","family":"ADVINCULA SOLIS","sequence":"additional","affiliation":[{"name":"Universidad Peruana Cayetano Heredia,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6031-1755","authenticated-orcid":false,"given":"Harold","family":"RAMOS MAMANI","sequence":"additional","affiliation":[{"name":"Universidad Peruana Cayetano Heredia,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9057-829X","authenticated-orcid":false,"given":"Hugo Guillermo","family":"CEDR\u00d3N CHENG","sequence":"additional","affiliation":[{"name":"Universidad Peruana Cayetano Heredia,  Peru; Cl\u00ednica Anglo Americana,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7710-0662","authenticated-orcid":false,"given":"\u00c1lvaro","family":"BELLIDO-CAPARO","sequence":"additional","affiliation":[{"name":"Universidad Peruana Cayetano Heredia,  Peru; Cl\u00ednica San Felipe,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1654-6924","authenticated-orcid":false,"given":"Dora","family":"MONTEZUMA CALVO","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Anglo Americana,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1569-8475","authenticated-orcid":false,"given":"Eduardo","family":"VESCO MONTEAGUDO","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Anglo Americana,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2370-1662","authenticated-orcid":false,"given":"G\u00fcnther","family":"POPPELE MOLINA","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Anglo Americana,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4409-6238","authenticated-orcid":false,"given":"Juan Antonio","family":"CHIRINOS VEGA","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Anglo Americana,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-8658","authenticated-orcid":false,"given":"Jorge","family":"ESPINOZA-R\u00cdOS","sequence":"additional","affiliation":[{"name":"Universidad Peruana Cayetano Heredia,  Peru; Cl\u00ednica San Felipe,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-2922","authenticated-orcid":false,"given":"Juan Sebasti\u00e1n","family":"FR\u00cdAS-ORDO\u00d1EZ","sequence":"additional","affiliation":[{"name":"International Hospital of Colombia,  Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-5369","authenticated-orcid":false,"given":"V\u00edctor","family":"AGUILAR S\u00c1NCHEZ","sequence":"additional","affiliation":[{"name":"Cl\u00ednica San Felipe,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-9537","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"PINTO VALDIVIA","sequence":"additional","affiliation":[{"name":"Universidad Peruana Cayetano Heredia,  Peru; Cl\u00ednica San Felipe,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7794-4438","authenticated-orcid":false,"given":"Jorge","family":"HUERTA MERCADO TENORIO","sequence":"additional","affiliation":[{"name":"Universidad Peruana Cayetano Heredia,  Peru; Cl\u00ednica Anglo Americana,  Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/j.gastro.2020.11.059","article-title":"AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review","volume":"160","author":"Shah SC","year":"2021","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.amjmed.2017.12.024","article-title":"Helicobacter pylori Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance","volume":"131","author":"Siddique O","year":"2018","journal-title":"Am J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/17460913.2025.2568326","article-title":"Diagnosis and treatment of Helicobacter pylori infection: past, present, and future","volume":"20","author":"Cho JH","year":"2025","journal-title":"Future Microbiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1128\/cmr.00258-21","article-title":"Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance","volume":"35","author":"Ansari S","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG Clinical Guideline: Treatment of Helicobacter pylori Infection","volume":"119","author":"Chey WD","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fmicb.2025.1652943","article-title":"Therapeutic advances and future directions in Helicobacter pylori eradication","volume":"16","author":"Suresh V","year":"2025","journal-title":"Front Microbiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ueg2.12476","article-title":"Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management","volume":"12","author":"Pab\u00f3n-Carrasco M","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"ref8","article-title":"High-dose dual therapy is superior to standard first-line or rescue therapy for helicobacter pylori infection","volume":"13","author":"Yang JC","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1053\/j.gastro.2024.06.038","article-title":"AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review","volume":"167","author":"Patel A","year":"2024","journal-title":"Gastroenterology"},{"key":"ref10","first-page":"1","article-title":"PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis","volume":"26","author":"Li C","year":"2021","journal-title":"Helicobacter"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/jpn3.12314","article-title":"Updated joint ESPGHAN\/NASPGHAN guidelines for management of Helicobacter pylori infection in children and adolescents (2023)","volume":"79","author":"Homan M","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(11)60825-8","article-title":"14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: A randomised trial","volume":"378","author":"Greenberg ER","year":"2011","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/ajg.2014.24","article-title":"The problem of helicobacter pylori resistance to antibiotics: A systematic review in latin America","volume":"109","author":"Camargo MC","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hel.13101","article-title":"Antimicrobial Resistance of Helicobacter pylori Isolated From Latin American Children and Adolescents (2008-2023): A Systematic Review","volume":"29","author":"Cabrera C","year":"2024","journal-title":"Helicobacter"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MCG.0000000000002064","article-title":"Efficacy and Safety of Standard Triple Therapy for Helicobacter pylori Eradication in Latin America A Systematic Review and Meta-Analysis","volume":"59","author":"D\u00edaz-Rodr\u00edguez DM","year":"2024","journal-title":"J Clin Gastroenterol"},{"key":"ref16","first-page":"767","article-title":"Estudio descriptivo del cumplimiento del tratamiento farmacol\u00f3gico antihipertensivo y validaci\u00f3n del test de Morisky y Green [Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test].","volume":"10","author":"Val Jim\u00e9nez A","year":"1992","journal-title":"Aten Primaria"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants","volume":"333","year":"2025","journal-title":"Jama"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MCG.0000000000001902","article-title":"The Efficacy and Safety of Regimens for Helicobacter pylori Eradication Treatment in China A Systemic Review and Network Meta-Analysis","volume":"58","author":"Li J","year":"2023","journal-title":"J Clin Gastroenterol"},{"key":"ref19","first-page":"2","article-title":"Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for Helicobacter pylori Infection: A Systematic Review","volume":"13","author":"Shih CA","year":"2025","journal-title":"Microorganisms"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/MCG.0000000000002100","article-title":"Clinical Impact of High-dose Esomeprazole-amoxicillin Dual Therapy as Rescue Treatment for Helicobacter pylori Infection: A Prospective, Multicenter, Randomized Trial","volume":"59","author":"Wang C","year":"2025","journal-title":"J Clin Gastroenterol"},{"key":"ref21","first-page":"151","article-title":"Resistencia antibi\u00f3tica de Helicobacter pylori en la poblaci\u00f3n peruana: una revisi\u00f3n sistem\u00e1tica y metaan\u00e1lisis sobre su prevalencia en la poblaci\u00f3n general [Antibiotic resistance of Helicobacter pylori in the Peruvian population: a systematic review and meta-analysis].","volume":"42","author":"Villavicencio Saque R","year":"2022","journal-title":"Rev Gastroenterol Peru"},{"key":"ref22","first-page":"15","article-title":"Recurrence rate of Helicobacter pylori infection two years after successful eradication in Peruvian patients presenting with postprandial distress syndrome","volume":"34","author":"Novoa Reyes I","year":"2014","journal-title":"Rev Gastroenterol Peru"},{"key":"ref23","first-page":"225","article-title":"Nuevo esquema simplificado para la erradicaci\u00f3n de Helicobacter pylori con alta efectividad. Estudio prospectivo en una cl\u00ednica privada de Lima, Per\u00fa [New simplified regimen for Helicobacter pylori eradication achieves high effectiveness. Prospective study in a private clinic in Lima, Peru].","volume":"37","author":"Barreda Costa CS","year":"2017","journal-title":"Rev Gastroenterol Peru"},{"key":"ref24","first-page":"113","article-title":"Comparaci\u00f3n de dosis est\u00e1ndar versus doble dosis de esomeprazol en la terapia de 14 d\u00edas de erradicaci\u00f3n de H. pylori","volume":"30","author":"Lubi RF","year":"2019","journal-title":"Gastroenterol Latinoam"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1157\/13127103","article-title":"Enfermedades relacionadas con el \u00e1cido. \u00bfSon m\u00e1s eficaces dosis m\u00e1s elevadas de inhibidores de la bomba de protones para el tratamiento de la infecci\u00f3n por Helicobacter pylori?","volume":"31","author":"Villoria Ferrer A","year":"2008","journal-title":"Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1365-2036.2008.03807.x","article-title":"Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication","volume":"28","author":"Villoria A","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano K","year":"2015","journal-title":"Gut"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hel.12723","article-title":"Searching for an optimal therapy for H pylori eradication: High-dose proton-pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days","volume":"25","author":"Hwong-Ruey Leow A","year":"2020","journal-title":"Helicobacter"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"14973","DOI":"10.3748\/wjg.v20.i40.14973","article-title":"Standard triple therapy for Helicobacter pylori infection in China: A meta-analysis","volume":"20","author":"Wang B","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/MCG.0000000000001448","article-title":"Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials","volume":"55","author":"Huang Q","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/sjg.sjg_532_22","article-title":"High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of helicobacter pylori infection: A meta-analysis of randomized controlled trials","volume":"29","author":"Zhang C","year":"2023","journal-title":"Saudi J Gastroenterol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","article-title":"Self-report measures of medication adherence behavior: recommendations on optimal use","volume":"5","author":"Stirratt MJ","year":"2015","journal-title":"Transl Behav Med"},{"key":"ref33","first-page":"241","article-title":"First-Line Eradication of Helicobacter pylori with High-Dose Dual Therapy Versus Quadruple Therapy with Bismuth for 14 Days: A Multicenter, Prospective and Randomized Study","volume":"52","author":"Llano RC","year":"2022","journal-title":"Acta Gastroenterol Latinoam"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CLEP.S178723","article-title":"Observational studies of treatment effectiveness: Worthwhile or worthless?","volume":"11","author":"Sharma M","year":"2019","journal-title":"Clin Epidemiol"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["Efic\u00e1cia no mundo real da terapia dupla em alta dose versus terapia tripla com claritromicina otimizada para Helicobacter Pylori: um estudo de coorte prospectivo com an\u00e1lises de sensibilidade do teste de cura"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032026000100209&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:34:50Z","timestamp":1786707290000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032026000100209&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":34,"alternative-id":["S0004-28032026000100209"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.24612026-014","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e26014"}}